CDTX - Cidara Therapeutics Inc EV/EBITDA Multiple

Cidara Therapeutics (CDTX) profitability is increasing due to the automation of drug synthesis via Cloudbreak. The company's EV/EBITDA ratio in a historical context demonstrates a trend where 0.00 serves as the final level mark. Revenues are based on the procurement of innovative medicines by hospitals and insurance funds. The current strategy relies on licensing deals and the development of antiviral treatment programs.

CDTX cidara.com: Business Value to Operating Income Before Depreciation in the range 11/23/2025 - 01/17/2026

Analytical breakdowns for Cidara Therapeutics

- stock price and consensus target price:

Stock Quotes cidara.com|CDTX - Price Target Chart

- market capitalization statistics:

Market Capitalization Cidara Corp|CDTX - Company Buyout Price

- issuer book value statistics:

Net Assets per Single Share Cidara|CDTX - Accounting Value of Company|Market Cap to Net Assets Ratio cidara.com|CDTX - Company Total Assets

- company liabilities and liquidity data:

- business earnings and investment ratios data:

CDTX - Net Profit|Expected Profit Cidara Therapeutics|CDTX - Company Value to Net Income|Forward P/E Multiple Cidara Therapeutics|CDTX - PEG Multiple|Enterprise Value to EBITDA Ratio Cidara Corp|CDTX - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Cidara|CDTX - Earnings per share for the last four quarters|Quarterly EPS earnings growth cidara.com|CDTX - Earnings per share increase in current year|Earnings growth forecast for next year Cidara Therapeutics

Analysis of all company metrics:Cidara Corp CDTX

Original product of Cidara Therapeutics, Inc.

Stability of raw material supplies through forwards protects the profitability of Cidara Therapeutics biotech production, making the analysis of the company's EV/EBITDA ratio critically important. This metric relates the total enterprise value to its operating profit before depreciation and taxes, allowing investors to objectively assess asset value relative to generated cash flow and avoid overpaying for overheated quotes.

Analysis of competing companies

Gilead Sciences Inc - Enterprise Value to EBITDA Ratio|Novavax Pharma - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CureVac N.V. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio valneva.com VALN|Vir Biotechnology (VIR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SIGA Technologies Inc - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio EBS|EV/EBITDA Multiple Atea Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Invivyd, Inc. (IVVD)|Total Company Value to Operating Income Before Depreciation Ratio enanta.com|EV/EBITDA Multiple INO (Inovio)|HLVX - Enterprise Value to EBITDA Ratio|Kalaris Therapeutics, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Dyadic International DYAI|NNVC: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation TLPH|COCP (Cocrystal Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple Traws Therapeutics|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Dogwood Therapeutics, Inc. (DWTX)|QLGN (Qualigen Corp) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ALVR (AlloVir)|EV/EBITDA Multiple VBI Vaccines, Inc. VBIV|VIRI: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation VXRT (Vaxart, Inc.)